NAMS Insider Trading

Insider Ownership Percentage: 19.50%
Insider Buying (Last 12 Months): $276,223.50
Insider Selling (Last 12 Months): $4,095,234.00

NewAmsterdam Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at NewAmsterdam Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NewAmsterdam Pharma Share Price & Price History

Current Price: $18.98
Price Change: Price Decrease of -0.43 (-2.22%)
As of 05/29/2024 01:00 AM ET

This chart shows the closing price history over time for NAMS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

NewAmsterdam Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2024James N TopperDirectorBuy8,429$21.50$181,223.503,008,429View SEC Filing Icon  
3/26/2024Johannes Jacob Piete KasteleinInsiderSell190,476$21.50$4,095,234.00View SEC Filing Icon  
2/13/2024Louis G LangeDirectorBuy5,000$19.00$95,000.0024,878View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for NewAmsterdam Pharma (NASDAQ:NAMS)

89.89% of NewAmsterdam Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NAMS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

NewAmsterdam Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/29/2024Opaleye Management Inc.315,388$7.46M1.6%+18.8%0.351%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.800,000$18.92M0.5%N/A0.896%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC636,231$15.02M0.0%N/A0.713%Search for SEC Filing on Google Icon
5/15/2024Baker BROS. Advisors LP96,827$2.29M0.0%N/A0.108%Search for SEC Filing on Google Icon
5/15/2024Affinity Asset Advisors LLC286,200$6.77M0.8%+129.0%0.321%Search for SEC Filing on Google Icon
5/14/2024StemPoint Capital LP80,334$1.90M0.5%N/A0.090%Search for SEC Filing on Google Icon
5/7/2024TimesSquare Capital Management LLC228,616$5.41M0.1%N/A0.256%Search for SEC Filing on Google Icon
5/2/2024Jennison Associates LLC930,851$22.02M0.0%N/A1.043%Search for SEC Filing on Google Icon
4/10/2024Yarbrough Capital LLC23,960$0.57M0.0%N/A0.027%Search for SEC Filing on Google Icon
3/7/2024Fcpm Iii Services B.V.11,831,461$132.16M39.2%N/A14.373%Search for SEC Filing on Google Icon
2/15/2024Opaleye Management Inc.265,388$2.96M0.8%N/A0.325%Search for SEC Filing on Google Icon
2/15/2024Parkman Healthcare Partners LLC300,750$3.36M0.5%+20.8%0.369%Search for SEC Filing on Google Icon
2/1/2024Wolverine Asset Management LLC8,694$97K0.0%+197.2%0.011%Search for SEC Filing on Google Icon
11/15/2023Affinity Asset Advisors LLC125,000$1.16M0.3%+25.0%0.153%Search for SEC Filing on Google Icon
11/14/2023Schonfeld Strategic Advisors LLC64,700$0.60M0.0%+12.9%0.079%Search for SEC Filing on Google Icon
11/13/2023Wolverine Asset Management LLC2,925$27K0.0%N/A0.004%Search for SEC Filing on Google Icon
8/21/2023Affinity Asset Advisors LLC100,000$1.19M0.4%N/A0.123%Search for SEC Filing on Google Icon
8/15/2023RA Capital Management L.P.9,000,000$107.01M2.0%+125.0%11.035%Search for SEC Filing on Google Icon
8/15/2023Bain Capital Life Sciences Investors LLC10,473,913$124.54M12.8%+26.2%12.842%Search for SEC Filing on Google Icon
8/10/2023Monashee Investment Management LLC95,000$1.13M0.3%N/A0.116%Search for SEC Filing on Google Icon
8/4/2023Maven Securities LTD25,000$0.30M0.0%N/A0.031%Search for SEC Filing on Google Icon
7/19/2023Medicxi Ventures Management Jersey Ltd2,869,565$34.12M9.6%+43.5%3.518%Search for SEC Filing on Google Icon
7/14/2023Venture Visionary Partners LLC10,000$0.12M0.0%N/A0.012%Search for SEC Filing on Google Icon
5/9/2023GMT Capital Corp1,083,800$14.37M0.6%+8.4%6.106%Search for SEC Filing on Google Icon
5/8/2023Wolverine Asset Management LLC4,819$64K0.0%N/A0.027%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.4,000,000$43.60M0.9%N/A22.535%Search for SEC Filing on Google Icon
2/3/2023Frazier Life Sciences Management L.P.9,341,551$101.82M6.3%N/A52.628%Search for SEC Filing on Google Icon
2/3/2023GMT Capital Corp1,000,000$10.90M0.5%N/A5.634%Search for SEC Filing on Google Icon
1/31/2023Medicxi Ventures Management Jersey Ltd2,000,000$21.80M9.2%N/A11.268%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More on NewAmsterdam Pharma

Today's Range

Now: $18.98
Low: $18.87
High: $19.79

50 Day Range

MA: $20.87
Low: $18.82
High: $23.65

52 Week Range

Now: $18.98
Low: $5.63
High: $26.35

Volume

103,242 shs

Average Volume

212,973 shs

Market Capitalization

$1.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

Who are the company insiders with the largest holdings of NewAmsterdam Pharma?

NewAmsterdam Pharma's top insider shareholders include:
  1. James N Topper (Director)
  2. Louis G Lange (Director)
  3. Johannes Jacob Piete Kastelein (Insider)
Learn More about top insider investors at NewAmsterdam Pharma.

Who are the major institutional investors of NewAmsterdam Pharma?

NewAmsterdam Pharma's top institutional shareholders include:
  1. Jennison Associates LLC — 1.04%
  2. Artal Group S.A. — 0.90%
  3. Janus Henderson Group PLC — 0.71%
  4. Opaleye Management Inc. — 0.35%
  5. Affinity Asset Advisors LLC — 0.32%
  6. TimesSquare Capital Management LLC — 0.26%
Learn More about top institutional investors of NewAmsterdam Pharma stock.

Which institutional investors are buying NewAmsterdam Pharma stock?

Within the previous quarter, NAMS stock was acquired by institutional investors including:
  1. Jennison Associates LLC
  2. Artal Group S.A.
  3. Janus Henderson Group PLC
  4. TimesSquare Capital Management LLC
  5. Affinity Asset Advisors LLC
  6. Baker BROS. Advisors LP
  7. StemPoint Capital LP
  8. Opaleye Management Inc.
During the previous year, these company insiders have bought NewAmsterdam Pharma stock:
  1. James N Topper (Director)
  2. Louis G Lange (Director)
Learn More investors buying NewAmsterdam Pharma stock.